These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33152818)

  • 41. Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells.
    Fiserová A; Hájek R; Holubová V; Büchler T; Sobotka J; Kovárová R; Musilová R; Bourková L; Buliková A; Mareschová I; Janácková Z; Váñová P; Kuglík P; Vorlícek J; Penka M
    Neoplasma; 2002; 49(5):300-6. PubMed ID: 12458327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
    Mellors PW; Binder M; Ketterling RP; Greipp PT; Baughn LB; Peterson JF; Jevremovic D; Pearce KE; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2020 May; 4(10):2236-2244. PubMed ID: 32442300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.
    Dong H; Yang HS; Jagannath S; Stephenson CF; Brenholz P; Mazumder A; Chari A
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):366-74. PubMed ID: 22658896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma.
    Ma ES; Wang CL; Wong AT; Choy G; Chan TL
    Mol Cytogenet; 2016; 9():63. PubMed ID: 27532015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
    Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
    Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases.
    Rack K; Vidrequin S; Dargent JL
    J Clin Pathol; 2016 Jan; 69(1):82-6. PubMed ID: 26338801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
    Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
    Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
    Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
    Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma.
    Stevens-Kroef M; Weghuis DO; Croockewit S; Derksen L; Hooijer J; Elidrissi-Zaynoun N; Siepman A; Simons A; Kessel AG
    Genes Chromosomes Cancer; 2012 Nov; 51(11):997-1006. PubMed ID: 22833442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma.
    Yu Y; Shen H; Liu L; Luo P; Wu S; He J; Tong X; Shang Y; Shao L; Zhou F
    J Vis Exp; 2022 Apr; (182):. PubMed ID: 35499349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application of FICTION technique to the detection of genetic aberrations in multiple myeloma].
    Wang D; Huang L; Zhang H; Geng Z; Shang Z; Zhou JF; Li CR
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):226-30. PubMed ID: 21569703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Frequency and prognostic value of chromosome abnormalities in multiple myeloma].
    Kurahashi S; Sawamoto A; Sugimoto T; Narimatsu H; Iwasaki T; Adachi T; Suzuki H; Hayakawa F; Sugiura I
    Rinsho Ketsueki; 2007 Nov; 48(11):1455-61. PubMed ID: 18080502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined cytogenetic testing and fluorescence in situ hybridization analysis in the study of chronic lymphocytic leukemia and multiple myeloma.
    Wiktor A; Van Dyke DL
    Cancer Genet Cytogenet; 2004 Aug; 153(1):73-6. PubMed ID: 15325099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma.
    Moore S; Suttle JM; Nicola M
    Methods Mol Biol; 2017; 1541():127-142. PubMed ID: 27910020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.